The investigational non-steroidal MRA balcinrenone in cardiorenal medicine: current evidence and future perspectives

Clicks: 12
ID: 330748
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #127 of 190 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 190 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract For almost 2 decades, renin-angiotensin-system (RAS)-blockade was the basic pillar of therapy for cardiorenal protection in patients with chronic kidney disease (CKD) and albuminuria. Novel therapies, such as sodium-glucose co-transporter type 2 inhibitors (SGLT2is) and the non-steroidal mineralocorticoid-receptor-antagonist (MRA) finerenone have been added to our therapeutic armamentarium in the last few years. Despite this substantial progress, there is still an unmet need for the development of additional therapies to mitigate the substantial residual risk of CKD patients. Balcinrenone is a novel, non-steroidal MRA that is currently under investigation for potential cardiorenal protective effects. In preclinical studies, balcinrenone was similarly effective with eplerenone in improving albuminuria and in reversing renal histopathology. Animal studies have shown a beneficial effect of balcinrenone on urinary sodium/potassium ratio that contrasts with the typical increase seen with traditional steroidal MRAs. The MIRO-CKD was a phase 2b trial showing that among 324 patients with albuminuric CKD, combination therapy with dapagliflozin and balcinrenone was safe and more effective than monotherapy with dapagliflozin in improving albuminuria over 3 months of follow-up. A large phase 3 clinical program is ongoing to investigate the long-term safety and efficacy of balcinrenone in a broad spectrum of patients with symptomatic heart failure and moderate-to-advanced CKD. In this article, we explore the tolerability, safety and efficacy of the investigational non-steroidal MRA balcinrenone. We critically evaluate the design and key findings of the MIRO-CKD trial and provide directions for future research in this important area.
Reference Key
openalex_W7215102767 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Panagiotis I. Georgianos, Sokratis Stoumpos, Christodoula Kourtidou, Evangelia C. Dounousi, Vassilios Liakopoulos, Patrick Barry Mark
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag347
URL
https://doi.org/10.1093/ckj/sfag347
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.